These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 29545180)

  • 1. Hepatic glucose-6-phosphatase-α deficiency leads to metabolic reprogramming in glycogen storage disease type Ia.
    Cho JH; Kim GY; Mansfield BC; Chou JY
    Biochem Biophys Res Commun; 2018 Apr; 498(4):925-931. PubMed ID: 29545180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of tumor-promoting pathways implicated in hepatocellular adenoma/carcinoma, a long-term complication of glycogen storage disease type Ia.
    Cho JH; Lee YM; Bae SH; Chou JY
    Biochem Biophys Res Commun; 2020 Jan; 522(1):1-7. PubMed ID: 31735334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ia at the tumor-developing stage.
    Cho JH; Lee YM; Starost MF; Mansfield BC; Chou JY
    J Inherit Metab Dis; 2019 May; 42(3):459-469. PubMed ID: 30637773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy.
    Lee YM; Jun HS; Pan CJ; Lin SR; Wilson LH; Mansfield BC; Chou JY
    Hepatology; 2012 Nov; 56(5):1719-29. PubMed ID: 22422504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia.
    Gjorgjieva M; Calderaro J; Monteillet L; Silva M; Raffin M; Brevet M; Romestaing C; Roussel D; Zucman-Rossi J; Mithieux G; Rajas F
    J Hepatol; 2018 Nov; 69(5):1074-1087. PubMed ID: 30193922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-α activity restored are at risk of developing hepatic tumors.
    Kim GY; Lee YM; Kwon JH; Cho JH; Pan CJ; Starost MF; Mansfield BC; Chou JY
    Mol Genet Metab; 2017 Mar; 120(3):229-234. PubMed ID: 28096054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging roles of autophagy in hepatic tumorigenesis and therapeutic strategies in glycogen storage disease type Ia: A review.
    Cho JH; Weinstein DA; Lee YM
    J Inherit Metab Dis; 2021 Jan; 44(1):118-128. PubMed ID: 32474930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy using a novel G6PC-S298C variant enhances the long-term efficacy for treating glycogen storage disease type Ia.
    Zhang L; Lee C; Arnaoutova I; Anduaga J; Starost MF; Mansfield BC; Chou JY
    Biochem Biophys Res Commun; 2020 Jun; 527(3):824-830. PubMed ID: 32430177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of SIRT1 signaling underlies hepatic autophagy impairment in glycogen storage disease type Ia.
    Cho JH; Kim GY; Pan CJ; Anduaga J; Choi EJ; Mansfield BC; Chou JY
    PLoS Genet; 2017 May; 13(5):e1006819. PubMed ID: 28558013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal hepatic glucose-6-phosphatase-α activity required to sustain survival and prevent hepatocellular adenoma formation in murine glycogen storage disease type Ia.
    Lee YM; Kim GY; Pan CJ; Mansfield BC; Chou JY
    Mol Genet Metab Rep; 2015 Jun; 3():28-32. PubMed ID: 26937391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The signaling pathways implicated in impairment of hepatic autophagy in glycogen storage disease type Ia.
    Gautam S; Zhang L; Arnaoutova I; Lee C; Mansfield BC; Chou JY
    Hum Mol Genet; 2020 Mar; 29(5):834-844. PubMed ID: 31961433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirtuin signaling controls mitochondrial function in glycogen storage disease type Ia.
    Cho JH; Kim GY; Mansfield BC; Chou JY
    J Inherit Metab Dis; 2018 May; ():. PubMed ID: 29740774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia.
    Zhou J; Waskowicz LR; Lim A; Liao XH; Lian B; Masamune H; Refetoff S; Tran B; Koeberl DD; Yen PM
    Thyroid; 2019 Aug; 29(8):1158-1167. PubMed ID: 31337282
    [No Abstract]   [Full Text] [Related]  

  • 14. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia.
    Lee YM; Pan CJ; Koeberl DD; Mansfield BC; Chou JY
    Mol Genet Metab; 2013 Nov; 110(3):275-80. PubMed ID: 23856420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of glycolysis and apoptosis in glycogen storage disease type Ia.
    Sun B; Li S; Yang L; Damodaran T; Desai D; Diehl AM; Alzate O; Koeberl DD
    Mol Genet Metab; 2009 Aug; 97(4):267-71. PubMed ID: 19419892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis of Hepatic Tumors following Gene Therapy in Murine and Canine Models of Glycogen Storage Disease.
    Kang HR; Gjorgjieva M; Smith SN; Brooks ED; Chen Z; Burgess SM; Chandler RJ; Waskowicz LR; Grady KM; Li S; Mithieux G; Venditti CP; Rajas F; Koeberl DD
    Mol Ther Methods Clin Dev; 2019 Dec; 15():383-391. PubMed ID: 31890731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained hepatic and renal glucose-6-phosphatase expression corrects glycogen storage disease type Ia in mice.
    Sun MS; Pan CJ; Shieh JJ; Ghosh A; Chen LY; Mansfield BC; Ward JM; Byrne BJ; Chou JY
    Hum Mol Genet; 2002 Sep; 11(18):2155-64. PubMed ID: 12189168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia.
    Waskowicz LR; Zhou J; Landau DJ; Brooks ED; Lim A; Yavarow ZA; Kudo T; Zhang H; Wu Y; Grant S; Young SP; Huat BB; Yen PM; Koeberl DD
    Hum Mol Genet; 2019 Jan; 28(1):143-154. PubMed ID: 30256948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanism underlying impaired hepatic autophagy in glycogen storage disease type Ib.
    Gautam S; Zhang L; Lee C; Arnaoutova I; Chen HD; Resaz R; Eva A; Mansfield BC; Chou JY
    Hum Mol Genet; 2023 Jan; 32(2):262-275. PubMed ID: 35961004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mice expressing reduced levels of hepatic glucose-6-phosphatase-α activity do not develop age-related insulin resistance or obesity.
    Kim GY; Lee YM; Cho JH; Pan CJ; Jun HS; Springer DA; Mansfield BC; Chou JY
    Hum Mol Genet; 2015 Sep; 24(18):5115-25. PubMed ID: 26089201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.